Table 2.
Predictors of Outcome for Older Patients Receiving Induction Chemotherapy for AML
| Study | No. of Patients | Treatment | Tumor Characteristics | Clinical Variables | Patient Characteristics | Outcome |
|---|---|---|---|---|---|---|
| Analyses from clinical trials | ||||||
| Kantarjian et al3 | 446 | Intensive | Complex karyotype | Creatinine > 1.3 mg/dL | Age > 80 years; ECOG PS > 1 | 8-week mortality |
| Krug et al48 | 1,406 | Intensive | Secondary AML/or prior hematologic disease; molecular/cytogenetic risk | Body temperature, hemoglobin, platelets, LDH, fibrinogen | Age | 60-day mortality; CR |
| Röllig et al49 | 909 | Intensive | Karyotype; NPM1-mutated CD34 expression > 10% | WBC > 20/μL; LDH > 700 U/L | Age > 65 years | Survival |
| Wheatley et al50 | 2,208 | Intensive | Cytogenetic risk group; secondary AML | WBC | Age, ECOG PS | 1-year survival |
| Geriatric assessment | ||||||
| Deschler et al51 | 107 | Nonintensive | Bone marrow blast percentage; cytogenetic risk group | Impaired ADLs; KPS < 80; high fatigue score, HCT-CI ≥ 3 | Survival | |
| Klepin et al52 | 74 | Intensive | Cytogenetic risk group; prior MDS | Hemoglobin | Cognitive impairment (3MS < 77); impaired physical performance (SPPB < 9) | Survival |
| Sherman et al53 | 101 | Mixed | Adverse cytogenetics; secondary AML | HCT-CI > 1; difficulty with strenuous activity; pain (more often v less); ECOG PS > 1 | Survival |
Abbreviations: 3MS, modified Mini–Mental State Exam; ADL, activity of daily living; AML, acute myeloid leukemia; CR, complete remission; ECOG, Eastern Cooperative Group; HCT-CI, hematopoietic cell transplantation comorbidity index; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; MDS, myelodysplastic syndromes; PS, performance status; SPPB, Short Physical Performance Battery.